Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24319681 | 0.85 | CRBN (0.67) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL23509388 | 0.85 | CRBN (0.67) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL24319836 | 0.85 | CRBN (0.67) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL22704248 | 0.83 | CRBN (0.67) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL25343190 | 0.83 | CRBN (0.67) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL24816877 | 0.83 | CRBN (0.67) | CRBNIKZF1IKZF2CSNK1A1 | |
| SCHEMBL30707579 | 0.82 | CRBN (0.63) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL501751 | 0.80 | CRBN (1.00) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL21760366 | 0.80 | CRBN (1.00) | CRBN | |
| SCHEMBL20046061 | 0.80 | CRBN (1.00) | CRBNDDB1IKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143822-A1 | BICYCLIC IMIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2021-07-22 | — | — | WO | disclosed |